WO2003104435A3 - Cancer-linked gene as target for chemotherapy - Google Patents

Cancer-linked gene as target for chemotherapy Download PDF

Info

Publication number
WO2003104435A3
WO2003104435A3 PCT/US2003/018742 US0318742W WO03104435A3 WO 2003104435 A3 WO2003104435 A3 WO 2003104435A3 US 0318742 W US0318742 W US 0318742W WO 03104435 A3 WO03104435 A3 WO 03104435A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
target
disclosed
chemotherapy
linked gene
Prior art date
Application number
PCT/US2003/018742
Other languages
French (fr)
Other versions
WO2003104435A2 (en
Inventor
Reinhard Ebner
Original Assignee
Avalon Pharmaceuticals
Reinhard Ebner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals, Reinhard Ebner filed Critical Avalon Pharmaceuticals
Priority to AU2003251515A priority Critical patent/AU2003251515A1/en
Publication of WO2003104435A2 publication Critical patent/WO2003104435A2/en
Publication of WO2003104435A3 publication Critical patent/WO2003104435A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cancer-linked gene sequences, and derived amino acid sequences, are disclosed along with processes for assaying potential an titumor agents based on their modulation of the expression of these cancer-linked genes. Also disclosed are antibodies that react with the disclosed polypeptides and methods of using the antibodies to treat cancerous conditions, such as by using the antibody to target cancerous cells in vivo for purposes of delivering therapeutic agents thereto. Also described are methods of diagnosing using the gene sequences.
PCT/US2003/018742 2002-06-10 2003-06-09 Cancer-linked gene as target for chemotherapy WO2003104435A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003251515A AU2003251515A1 (en) 2002-06-10 2003-06-09 Cancer-linked gene as target for chemotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38739902P 2002-06-10 2002-06-10
US60/387,399 2002-06-10

Publications (2)

Publication Number Publication Date
WO2003104435A2 WO2003104435A2 (en) 2003-12-18
WO2003104435A3 true WO2003104435A3 (en) 2004-07-01

Family

ID=29736308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018742 WO2003104435A2 (en) 2002-06-10 2003-06-09 Cancer-linked gene as target for chemotherapy

Country Status (2)

Country Link
AU (1) AU2003251515A1 (en)
WO (1) WO2003104435A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127567A1 (en) * 2000-08-31 2002-09-12 Glucksmann Maria A. 52991, a novel human transporter and uses therefor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127567A1 (en) * 2000-08-31 2002-09-12 Glucksmann Maria A. 52991, a novel human transporter and uses therefor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAMBE, M. ET AL.: "Enhancement of Chemotherapeutic Effects with Focused Shock Waves: Extracorporeal Shock Wave Chemotherapy (ESWC)", IN VIVO, vol. 10, no. 3, 1996, pages 369 - 375, XP002974897 *
OZOREN N. ET AL.: "Heat Shock Protects HCT116 and H460 Cells from TRAIL-Induced Apoptosis", EXPERIMENTAL CELL RESEARCH, vol. 281, no. 2, 2002, pages 175 - 181, XP002974896 *
RITZEL, M. W. L. ET AL.: "Molecular Identification and Characterization of Novel Human and Mouse Concentrative Na+-Nucleoside Cotransporter Proteins (hCNT3 and mCNT3) Broadly Selective for Purine and Pyrimidine Nucleosides (System cib)", J. BIOL. CHEM., vol. 276, no. 4, 2001, pages 2914 - 2927, XP002974895 *

Also Published As

Publication number Publication date
AU2003251515A1 (en) 2003-12-22
WO2003104435A2 (en) 2003-12-18
AU2003251515A8 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
WO2003105758A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104399A3 (en) Cancer-linked gene as target for chemotherapy
WO2003097803A3 (en) Cancer-linked gene as target for chemotherapy
WO2003101400A3 (en) Cancer-linked gene as target for chemotherapy
WO2008020596A3 (en) Treating or preventing cancers over-expressing reg4 or kiaa0101
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
TW200728465A (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP1004022A4 (en) Methods and compositions for overcoming resistance to biologic and chemotherapy
BRPI0315666B8 (en) a34 and a33 type 3 DNA, proteins, their antibodies and treatment methods using them
MX2009013646A (en) Methods of diagnosing and treating cancer.
CR20220317A (en) Anti-cd73 antibodies and uses thereof
DE69837754D1 (en) COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN NEOPLASMABEL TREATMENT
WO2005120588A3 (en) Peptides delivered to cell nuclei
WO2004078215A3 (en) Use of antibody conjugated deoxycytidine kinase for adept
MXPA05011085A (en) Compositions and methods relating to stop-1.
WO2003104438A3 (en) Cancer-linked gene as target for chemotherapy
WO2003104401A3 (en) Cancer-linked gene as target for chemotherapy
WO2003076579A3 (en) Cancer-linked gene as target for chemotherapy
WO2004026238A8 (en) Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers
WO2003097802A3 (en) Cancer-linked gene as target for chemotherapy
WO2003105783A3 (en) Cancer-linked gene as target for chemotherapy
WO2002031198A3 (en) Cancer-linked genes as targets for chemotherapy
WO2005062788A3 (en) Prostate specific proteins expressed in cancer and methods of use thereof
WO2003104419A3 (en) Cancer-linked gene as target for chemotherapy
WO2003076587A3 (en) Cancer-linked gene as target for chemotherapy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP